- Conditions
- Solid Tumor, Adult
- Interventions
- GAd-209-FSP low dose, MVA-209-FSP low dose, GAd-209-FSP high dose, MVA-209-FSP high dose, GAd20-209-FSP, RP2D, MVA-209-FSP, RP2D, KEYTRUDA®
- Biological · Drug
- Lead sponsor
- Nouscom SRL
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 13
- States / cities
- Duarte, California • Irvine, California • Los Angeles, California + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 277
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Recurrent Gastric Cancer, Stage IIIA Gastric Cancer, Stage IIIB Gastric Cancer, Stage IIIC Gastric Cancer, Stage IV Gastric Cancer
- Interventions
- alvocidib, irinotecan hydrochloride, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 5
- States / cities
- Duarte, California • Sacramento, California • Chicago, Illinois + 2 more
- Conditions
- Esophageal Cancer, Gastric Cancer
- Interventions
- Oxaliplatin, Leucovorin, Fluorouracil, Ziv-aflibercept
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Esophageal Cancer, Gastric Cancer
- Interventions
- cisplatin, irinotecan hydrochloride, paclitaxel, conventional surgery, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2009
- U.S. locations
- 23
- States / cities
- Denver, Colorado • Newark, Delaware • Gainesville, Florida + 17 more
- Conditions
- Central Nervous System Lymphoma, Gastric Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Non-Hodgkin Lymphoma, Splenic Mantle Cell Lymphoma
- Interventions
- Akt/ERK Inhibitor ONC201, Laboratory Biomarker Analysis, Pharmacological Study
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Brain Tumors, Gastric Cancer, Ovarian Cancer, Prostate Cancer
- Interventions
- KLH, GMCSF
- Biological
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2008
- U.S. locations
- 13
- States / cities
- Bay City, Michigan • Port Huron, Michigan • Bellingham, Washington + 6 more
- Conditions
- Gastrointestinal Cancer, Pancreatic Cancer, Gastric Cancer, Colon Cancer, Rectal Cancer
- Interventions
- Cyclophosphamide, Fludarabine, Aldesleukin, anti-Kirsten rat sarcoma virus (KRAS) Glycine(G) to Aspartic Acid(D) substitution at codon 12 peripheral blood lymphocytes (PBL), EKG, CT, MRI, PET, Chest x-ray, Photography
- Drug · Biological · Diagnostic Test + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 72 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Depression, Fatigue, Stage IIA Colorectal Cancer, Stage IIB Colorectal Cancer, Stage IIC Colorectal Cancer, Stage IIIA Colorectal Cancer, Stage IIIB Colorectal Cancer, Stage IIIC Colorectal Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer, Pancreatic Cancer, Esophageal Cancer, Appendix Cancer, Stomach Cancer, Gallbladder Cancer, Liver Cancer, Small Intestine Cancer, Large Intestine Cancer, Anal Cancer, Biliary Tract Cancer, Gastrointestinal Stromal Cancer
- Interventions
- Laboratory Biomarker Analysis, Questionnaire Administration, Daily Survey Administration, Yoga Skills Training, Attention Control, Actigraphy Assessment
- Other · Behavioral
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 2
- States / cities
- Winston-Salem, North Carolina • Nashville, Tennessee
- Conditions
- Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, Colorectal Cancer
- Interventions
- Zongertinib, Trastuzumab deruxtecan, Trastuzumab emtansine, Trastuzumab, Capecitabine, mFOLFOX6, zanidatamab
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 768 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 26
- States / cities
- Cerritos, California • Los Angeles, California • Orange, California + 18 more
- Conditions
- Advanced Malignant Solid Neoplasm, Advanced Biliary Tract Carcinoma, Advanced Esophageal Carcinoma, Metastatic Esophageal Carcinoma, Locally Advanced Colorectal Carcinoma, Locally Advanced Esophageal Carcinoma, Locally Advanced Gastric Carcinoma, Metastatic Colorectal Carcinoma (mCRC), Advanced Lung Carcinoma, Locally Advanced Hepatocellular Carcinoma
- Interventions
- Olanzapine, Placebo Administration, Questionnaire Administration
- Drug · Other
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Esophageal, Gastrooesophageal Cancer, Gastric Cancer
- Interventions
- jevtana
- Drug
- Lead sponsor
- howard safran
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 3
- States / cities
- Pawtucket, Rhode Island • Providence, Rhode Island
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Diffuse Gastric Adenocarcinoma, Gastric Intestinal Type Adenocarcinoma, Gastric Mixed Adenocarcinoma, Recurrent Gastric Carcinoma
- Interventions
- Akt Inhibitor MK2206
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 186
- States / cities
- Mobile, Alabama • Fairbanks, Alaska • Tucson, Arizona + 124 more
- Conditions
- Neoplasms, Gastrointestinal Tract
- Interventions
- Lapatinib and Capecitabine
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 8
- States / cities
- Loma Linda, California • Los Angeles, California • Washington D.C., District of Columbia + 5 more
- Conditions
- Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
- Interventions
- AZD4360
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- Santa Monica, California • Providence, Rhode Island • Houston, Texas
- Conditions
- Advanced Solid Tumors, Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Gastroesophageal Junction Cancer
- Interventions
- MRG002
- Drug
- Lead sponsor
- Shanghai Miracogen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 2
- States / cities
- Orange, California • Houston, Texas
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Recurrent Gastric Cancer, Stage IIIA Gastric Cancer, Stage IIIB Gastric Cancer, Stage IIIC Gastric Cancer, Stage IV Gastric Cancer
- Interventions
- irinotecan hydrochloride, bevacizumab, cisplatin, computed tomography, laboratory biomarker analysis
- Drug · Biological · Procedure + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction
- Interventions
- Tesetaxel
- Drug
- Lead sponsor
- Genta Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Philadelphia, Pennsylvania • Houston, Texas
- Conditions
- Stomach Neoplasms
- Interventions
- Docetaxel + Oxaliplatin, Docetaxel + Oxaliplatin + 5-FU, Docetaxel + Oxaliplatin + Capecitabine
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Extrahepatic Bile Duct Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Liver Cancer, Pancreatic Cancer, Small Intestine Cancer
- Interventions
- filgrastim, recombinant interferon alfa, fluorouracil, hydroxyurea
- Biological · Drug
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2000
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Esophageal Cancer
- Interventions
- fluorouracil, oxaliplatin, conventional surgery, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Albany Medical College
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2004
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Peritoneal Carcinomatosis
- Interventions
- Cisplatin, Hyperthermic Intraperitoneal Chemotherapy, Mitomycin
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Gastro Esophageal Junction Cancer, Stomach Cancer, Adenocarcinoma
- Interventions
- Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab, Adjuvant Treatment - mFOLFOX & Pembrolizumab
- Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Westwood, Kansas
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Recurrent Gastric Cancer, Stage IIIB Gastric Cancer, Stage IIIC Gastric Cancer, Stage IV Gastric Cancer
- Interventions
- bortezomib, irinotecan
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2013
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Adenocarcinoma
- Interventions
- Lapatinib (GW572016) oral tablets
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Ann Arbor, Michigan • Buffalo, New York